#United States #New York #Kodiak Sciences #KOD #Victor Perlroth

Kodiak Sciences to Present at the 2026 Jefferies Global Healthcare Conference

PALO ALTO, Calif. - Kodiak Sciences Inc. (Nasdaq: KOD), a pioneering biotechnology firm focusing on retina health, has an exciting announcement regarding its participation in the 2026 Jefferies Global Healthcare Conference. The company’s Chief Executive Officer, Dr. Victor Perlroth, will present at this prominent event on June 4, 2026, at 11:40 AM ET.

As a precommercial company dedicated to advancing therapeutics for retinal diseases, Kodiak Sciences aims to shed light on its pivotal contributions to the healthcare field. The Jefferies Global Healthcare Conference is a platform for industry leaders to share insights and innovations—which is a perfect venue for Kodiak to highlight its commitment to combating blindness with cutting-edge solutions.

Key Presentation Details

Dr. Perlroth’s presentation will focus on Kodiak Sciences’ ongoing projects, particularly its late-stage clinical programs. These include the promising Zenkuda™ (tarcocimab tedromer) alongside other candidates, KSI-501 and KSI-101, which are all designed to address significant retinal conditions. The opportunity to present at this leading healthcare conference underscores Kodiak’s mission to bring transformative therapies to patients suffering from visual impairments.

Live Webcast Available

For those unable to attend the conference in person, Kodiak Sciences will offer a live webcast of the presentation. This can be accessed via the 'Events and Presentations' section on Kodiak's corporate website. Additionally, the presentation will remain available for replay shortly after the live event concludes, allowing stakeholders and interested parties to engage with the content at their convenience.

About Kodiak Sciences Inc.

Founded with the vision of revolutionizing retinal medicine, Kodiak Sciences is dedicated to researching, developing, and commercializing innovative therapeutic options targeting the leading causes of blindness worldwide. The company’s strategy is focused on harnessing next-generation science to create retinal medications that can significantly improve patient outcomes. With a robust pipeline consisting of multiple late-stage programs, Kodiak continues to position itself as a leader in the biotechnology industry, addressing the urgent needs of those with retinal disorders.

Kodiak Sciences is committed to excellence and innovation, ensuring that life-changing therapies reach those who need them most. Their brand is built on a foundation of scientific rigor and dedication to patient care, making their upcoming presentation at the Jefferies Conference a critical moment to disseminate valuable insights to the broader medical and investor community.

Conclusion

The presentation at the Jefferies Global Healthcare Conference is a testament to Kodiak Sciences’ efforts and advancements in the field of retinal therapy. As the event draws closer, anticipation builds around the potential breakthroughs showcased by Dr. Perlroth and his team. Interested individuals are encouraged to tune into the live webcast and explore the latest innovations that Kodiak Sciences is bringing to the forefront of biotechnology.